CD34 and non-Hodgkin lymphoma: Additional data are available from a European plerixafor compassionate use program reported by Hübel et al. [14], which enrolled 270 patients with NHL who had previously failed mobilization/collection, or who were determined to be unable to mobilize sufficient HSCs based on peripheral blood CD34+ cell counts during mobilization.